Poster, Podium & Video Sessions
Presentation Authors: Nicola Macchione*, Michele Catalani, Milano, Italy
Introduction: Chronic prostatitis/chronic pelvic pain syndrome are reported in literature ranging from 1 to 14,2%. Category III prostatitis is called chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and by definition it is characterized by pelvic pain for more than 3 of the previous 6 months, urinary symptoms and painful ejaculation, without documented urinary tract infections from uropathogens. The focus of therapy is pain relief and in the last years the research is addressed to find some phitotherapic solutions. The aim of the present study was to assess the impact on the patient’s quality of life and symptoms of Deprox 500 ® in comparison with Serenoa Repens 320 mg.
Methods: This is a single-center randomized controlled trial, comparing the efficacy and the IPSS/NIH-CPSI score variation in patients with CP/CPPS. All consecutive patients with a diagnosis of CP/CPPS referred to our center from January 2016 to August 2016 were screened to be enrolled in this study. The first outcome was the evaluation of IPSS/NIH-CPSI score variation and the assessment of the quality of life and symptoms at the end of the therapy. The second outcome was to evaluate the role of comorbidity in the CP/CPPS therapy. Patients with medical treatment for LUTS such as alfa-blocker or 5-ARI, major concomitant diseases and with residual urine volume >50 ml were not included in this study. All patients were randomized in two groups; one was treated with Deprox 500 ® mg 2 tabs/day for 6 weeks and the other with Serenoa Repens 320 mg, 1 tab/day for 6 weeks.
Results: A total of 63 patients concluded the therapy and were included in the data analysis. Of those patients 29 were treated with Deprox 500 ® and 34 with Serenoa Repens. The mean score variation was IPSS -12,7 + 4.3 for Deprox and IPSS - 7.8 + 4.7 for Serenoa Repens (p-value = 0.0005) and NIH-CPSI -17.3 + 3.1 for Deprox and NIH-CPSI - 13.6 + 4.8 for Serenoa Repens (p-value = 0.0016). By accounting only the symptoms part of NIH-CPSI questionnaire, the mean score variation reported was - 11.5 + 2.5 for Deprox group and - 9.02 + 4.0 for Serenoa Repens group (p value = 0.009321). Furthermore, by analysing the comorbidity subgroups, in patients with hypertension the mean IPSS score variation was -14.3 + 3.2 for Deprox and - 9.02 + 4.0 for Serenoa Repens.
Conclusions: Deprox 500 ® appears to be more effective in patients with CP/CPSI; improving IPSS and NIH-CPSI scores up to 74.5% and 84.5% respectively. Furthermore, in patients with hypertension the antioxidant effect of Deprox 500 ® reduces the mean IPSS score of 82.7%.
Source Of Funding: none
Università degli Studi di Milano
Nicola Macchione, MD,
ASST SAnti Paolo e Carlo
Univarsità degli Studi di Milano
I am a young italian urologist working in an academic hospital of Milano (ASST-Santi Paolo e Carlo) in the south area of the city.
I am EAU Member and associated member of the EULIS group (European Association of Urology-Urolithiasis section).